EFFECT OF BASELINE EPO AND PRIOR ERYTHROPOIESIS STIMULATING AGENTS ON RBC TRANSFUSION INDEPENDENCE IN LOW-/INT-1-RISK MDS WITH DEL5Q TREATED WITH LENALIDOMIDE: A RANDOMIZED PHASE 3 STUDY (MDS-004)

被引：0
|
作者：
Fenaux, P. [1 ]
Giagounidis, A. [2 ]
Selleslag, D. [3 ]
Knight, R. [4 ]
Fu, T. [4 ]
Hellstrom-Lindberg, E. [5 ]
机构：
[1] Univ Paris 13, Hop Avicenne, Bobigny, France
[2] St Johannes Hosp, Duisburg, Germany
[3] AZ St Jan Brugge AV, Brugge, Belgium
[4] Celgene Corp, Summit, NJ USA
[5] Karolinska Univ, Huddinge Hosp, Stockholm, Sweden
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0311
引用
收藏
页码：125 / 125
页数：1
相关论文
共 44 条
  • [41] Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study
    Platzbecker, Uwe
    Komrokji, Rami S.
    Fenaux, Pierre
    Zeidan, Amer M.
    Sekeres, Mikkael A.
    Savona, Michael Robert
    Madanat, Yazan F.
    Santini, Valeria
    Van Eygen, Koen
    Raza, Azra
    Germing, Ulrich
    Berry, Tymara
    Dougherty, Souria
    Shah, Sheetal
    Sun, Libo
    Huang, Fei
    Feller, Faye
    Wan, Ying
    Ikin, Annat
    Sherman, Laurie
    BLOOD, 2022, 140 : 1106 - 1108
  • [42] Activity of Lenalidomide in a Phase II Single Institution Study in Non-Del(5q) Transfusion Dependent, Patients with Low and Intermediate-1 Risklower-Risk, Non-Del(5q) Myelodysplastic Syndromes (MDS))): Results From a Single-Institution Phase II Study
    Raza, Azra
    Falkenstern, John
    Yeh, Fiona
    Castagna, Ginevra
    De Los Reyes, Antonietta
    Galili, Naomi
    BLOOD, 2012, 120 (21)
  • [43] Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence ( RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study
    Komrokji, Rami S.
    Santini, Valeria
    Fenaux, Pierre
    Savona, Michael R.
    Madanat, Yazan F.
    Berry, Tymara
    Sherman, Laurie
    Navada, Shyamala
    Feller, Faye M.
    Sun, Libo
    Xia, Qi
    Wan, Ying
    Huang, Fei
    Zeidan, Amer M.
    Platzbecker, Uwe
    BLOOD, 2023, 142
  • [44] IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESA).
    Zeidan, Amer Methqal
    Platzbecker, Uwe
    Santini, Valeria
    Fenaux, Pierre
    Sekeres, Mikkael A.
    Savona, Michael R.
    Madanat, Yazan F.
    Diez-Campelo, Maria
    Valcarcel, David
    Illmer, Thomas
    Jonasova, Anna
    Belohlavkova, Petra
    Sherman, Laurie Jill
    Berry, Tymara
    Dougherty, Souria
    Shah, Sheetal
    Sun, Libo
    Wan, Ying
    Huang, Fei
    Komrokji, Rami S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345